

# Mirco Ponzoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5345960/publications.pdf>

Version: 2024-02-01

164  
papers

6,111  
citations

61984

43  
h-index

91884

69  
g-index

166  
all docs

166  
docs citations

166  
times ranked

7693  
citing authors

#	ARTICLE	IF	CITATIONS
1	Macrophages Are Alternatively Activated in Patients with Endometriosis and Required for Growth and Vascularization of Lesions in a Mouse Model of Disease. <i>American Journal of Pathology</i> , 2009, 175, 547-556.	3.8	319
2	Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. <i>Cancer Research</i> , 2003, 63, 7400-9.	0.9	242
3	Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy. <i>Cancer Research</i> , 2006, 66, 10073-10082.	0.9	215
4	Expression of $^{125}\text{I}$ Np73 is a molecular marker for adverse outcome in neuroblastoma patients. <i>Cell Death and Differentiation</i> , 2002, 9, 246-251.	11.2	183
5	Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. <i>Clinical Cancer Research</i> , 2003, 9, 2032-9.	7.0	151
6	Spot overlapping in two-dimensional maps: A serious problem ignored for much too long. <i>Proteomics</i> , 2005, 5, 2385-2395.	2.2	130
7	Effect of Bortezomib on Human Neuroblastoma Cell Growth, Apoptosis, and Angiogenesis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1142-1157.	6.3	125
8	Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. <i>Cancer Research</i> , 2003, 63, 86-92.	0.9	122
9	Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. <i>Science Translational Medicine</i> , 2015, 7, 283ra55.	12.4	120
10	Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1953.	4.1	117
11	Targeted Drug Delivery and Penetration Into Solid Tumors. <i>Medicinal Research Reviews</i> , 2012, 32, 1078-1091.	10.5	108
12	Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. <i>Molecular Cancer</i> , 2007, 6, 8.	19.2	106
13	Delivery of c-myc Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects. <i>Journal of the National Cancer Institute</i> , 2000, 92, 253-261.	6.3	98
14	A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects. <i>Journal of Controlled Release</i> , 2016, 223, 165-177.	9.9	89
15	Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin. <i>Clinical Cancer Research</i> , 2008, 14, 7320-7329.	7.0	82
16	Tumor Vascular Targeting with Tumor Necrosis Factor $\alpha$ and Chemotherapeutic Drugs. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 104-112.	3.8	78
17	Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. <i>Journal of Controlled Release</i> , 2010, 145, 66-73.	9.9	78
18	Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis. <i>Clinical Cancer Research</i> , 2007, 13, 3977-3988.	7.0	77

#	ARTICLE	IF	CITATIONS
19	Critical Role of Flanking Residues in NGR-to-isoDGR Transition and CD13/Integrin Receptor Switching. <i>Journal of Biological Chemistry</i> , 2010, 285, 9114-9123.	3.4	77
20	Expression and methylation of CASP8 in neuroblastoma: Identification of a promoter region. <i>Nature Medicine</i> , 2002, 8, 1333-1335.	30.7	76
21	Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor. <i>Clinical Cancer Research</i> , 2010, 16, 4809-4821.	7.0	74
22	Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. <i>International Journal of Cancer</i> , 1997, 70, 688-698.	5.1	68
23	Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt. <i>Scientific Reports</i> , 2016, 6, 25092.	3.3	67
24	Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma. <i>Cancer Research</i> , 2010, 70, 9816-9826.	0.9	65
25	A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. <i>Molecular Therapy</i> , 2017, 25, 218-231.	8.2	65
26	Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational <sup>18</sup> F-FDG PET/CT Observation. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1638-1645.	5.0	65
27	Inhibition of neuroblastoma-induced angiogenesis by fenretinide. <i>International Journal of Cancer</i> , 2001, 94, 314-321.	5.1	63
28	Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. <i>Oncogene</i> , 2005, 24, 6785-6795.	5.9	63
29	Angiogenesis in Neuroblastoma. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 133-142.	3.8	62
30	Immune Cell-Mediated Antitumor Activities of GD2-Targeted Liposomal c-myc Antisense Oligonucleotides Containing CpG Motifs. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1171-1180.	6.3	61
31	Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. <i>Life Sciences</i> , 2001, 68, 1161-1168.	4.3	58
32	GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. , 1999, 81, 268-274.		57
33	Potent and sustained inhibition of HIF-1 $\alpha$ and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. <i>Angiogenesis</i> , 2011, 14, 245-53.	7.2	57
34	Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. <i>Molecular Therapy</i> , 2011, 19, 2201-2212.	8.2	57
35	Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK. <i>Molecular Therapy</i> , 2011, 19, 1131-1140.	8.2	56
36	Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. , 1998, 77, 449-454.		54

#	ARTICLE	IF	CITATIONS
37	Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. <i>Clinical Cancer Research</i> , 2003, 9, 4595-605.	7.0	53
38	In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. <i>International Journal of Cancer</i> , 2002, 102, 351-354.	5.1	52
39	Angiogenesis and anti-angiogenesis in neuroblastoma. <i>European Journal of Cancer</i> , 2002, 38, 750-757.	2.8	49
40	Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. <i>Molecular Immunology</i> , 2006, 43, 1509-1518.	2.2	49
41	Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. <i>Journal of Controlled Release</i> , 2015, 211, 44-52.	9.9	49
42	Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. <i>Cancer Letters</i> , 2003, 197, 231-235.	7.2	47
43	Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon-sensitive response element (ISRE). <i>Cell Death and Differentiation</i> , 2004, 11, 131-134.	11.2	46
44	Recent advances in the developmental origin of neuroblastoma: an overview. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 92.	8.6	46
45	ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. <i>Cancer Research</i> , 2014, 74, 6094-6106.	0.9	45
46	Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. <i>Molecular Cancer</i> , 2010, 9, 137.	19.2	44
47	Antiangiogenic strategies in neuroblastoma. <i>Cancer Treatment Reviews</i> , 2005, 31, 27-34.	7.7	43
48	The use of the orthotopic model to validate antivascular therapies for cancer. <i>International Journal of Developmental Biology</i> , 2011, 55, 547-555.	0.6	43
49	Targeted delivery of antisense oligonucleotides in cancer. <i>Journal of Controlled Release</i> , 2001, 74, 69-75.	9.9	42
50	Autocrine Regulation of Volume-sensitive Anion Channels in Airway Epithelial Cells by Adenosine. <i>Journal of Biological Chemistry</i> , 1999, 274, 11701-11707.	3.4	41
51	In vitro and in vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma. <i>International Journal of Cancer</i> , 2003, 104, 559-567.	5.1	41
52	Development of Fab <sup>2</sup> fragments of anti-GD2 immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 199-204.	7.2	41
53	Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. <i>Journal of Controlled Release</i> , 2013, 170, 233-241.	9.9	41
54	Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. <i>Journal of Controlled Release</i> , 2013, 170, 445-451.	9.9	41

#	ARTICLE	IF	CITATIONS
55	Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. <i>Journal of Controlled Release</i> , 2019, 308, 44-56.	9.9	41
56	PHOX2B-Mediated Regulation of ALK Expression: In Vitro Identification of a Functional Relationship between Two Genes Involved in Neuroblastoma. <i>PLoS ONE</i> , 2010, 5, e13108.	2.5	40
57	Study of proteomic changes associated with healthy and tumoral murine samples in neuroblastoma by principal component analysis and classification methods. <i>Clinica Chimica Acta</i> , 2004, 345, 55-67.	1.1	39
58	The Combined Therapeutic Effects of Bortezomib and Fenretinide on Neuroblastoma Cells Involve Endoplasmic Reticulum Stress Response. <i>Clinical Cancer Research</i> , 2009, 15, 1199-1209.	7.0	39
59	Protein kinase C isoenzymes in human neuroblasts involvement of PKC $\mu$ in cell differentiation. <i>FEBS Letters</i> , 1993, 322, 120-124.	2.8	37
60	Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. <i>Cancer Letters</i> , 2003, 197, 205-209.	7.2	37
61	Role of methylation in the control of $\beta$ -Np73 expression in neuroblastoma. <i>Cell Death and Differentiation</i> , 2002, 9, 343-345.	11.2	36
62	Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 151-155.	7.2	36
63	Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. <i>Biomaterials</i> , 2015, 68, 89-99.	11.4	36
64	Uncoordinate induction and differential regulation of hla class-I and class-II expression by $\beta$ -interferon in differentiating human neuroblastoma cells. <i>International Journal of Cancer</i> , 1993, 55, 817-823.	5.1	35
65	Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. <i>Scientific Reports</i> , 2013, 3, 1351.	3.3	34
66	Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers. <i>Small</i> , 2019, 15, e1804591.	10.0	34
67	Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. <i>Journal of Cellular Biochemistry</i> , 2003, 89, 698-708.	2.6	33
68	Caspase-8 Gene Expression in Neuroblastoma. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 157-167.	3.8	33
69	Neuroblastoma targeting by c-myc-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities. <i>Cancer Letters</i> , 2005, 228, 181-186.	7.2	29
70	Increased myocardial $^{18}$ F-FDG uptake as a marker of Doxorubicin-induced oxidative stress. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 2183-2194.	2.1	29
71	N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells <i>In Vitro</i> through induction of programmed cell death. , 1999, 81, 262-267.		28
72	Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF- $\kappa$ B and Mat1A genes in the early stages of rat liver carcinogenesis. <i>Carcinogenesis</i> , 2004, 26, 417-427.	2.8	28

#	ARTICLE	IF	CITATIONS
73	Ligand-Targeted Liposomal Therapies of Neuroblastoma. <i>Current Medicinal Chemistry</i> , 2007, 14, 3070-3078.	2.4	28
74	Modulation of $\alpha 1 \beta 1$ , $\alpha 2 \beta 1$ , and $\alpha 3 \beta 1$ integrin heterodimers during human neuroblastoma cell differentiation. <i>FEBS Letters</i> , 1993, 332, 263-267.	2.8	27
75	Combined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models. <i>Small</i> , 2020, 16, e1906426.	10.0	27
76	Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 180.	8.6	27
77	Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. <i>Journal of Controlled Release</i> , 2008, 126, 85-94.	9.9	26
78	Quiescent Hepatic Stellate Cells Functionally Contribute to the Hepatic Innate Immune Response via TLR3. <i>PLoS ONE</i> , 2014, 9, e83391.	2.5	26
79	sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib. <i>Journal of Controlled Release</i> , 2014, 192, 157-166.	9.9	26
80	Microfragmented human fat tissue is a natural scaffold for drug delivery: Potential application in cancer chemotherapy. <i>Journal of Controlled Release</i> , 2019, 302, 2-18.	9.9	26
81	Gut Bacteria and their Metabolites: Which One Is the Defendant for Colorectal Cancer?. <i>Microorganisms</i> , 2019, 7, 561.	3.6	25
82	Abstract 5609: Bortezomib enhanced cytotoxic effects of novel sTRAIL-targeted nanocarriers against neuroectodermal tumors .. <i>Cancer Research</i> , 2013, 73, 5609-5609.	0.9	24
83	Effects of $\gamma$ -interferon on the growth, morphology, and membrane and cytoskeletal proteins expression of LAN-1 cells. <i>Experimental Cell Research</i> , 1989, 185, 327-341.	2.6	23
84	A combined evaluation of biochemical and morphological changes during human neuroblastoma cell differentiation. <i>Cellular and Molecular Neurobiology</i> , 1992, 12, 225-240.	3.3	23
85	Synergistic Differentiation-Promoting Activity of Interferon $\gamma$ and Tumor Necrosis Factor- $\alpha$ : Role of Receptor Regulation on Human Neuroblasts. <i>Journal of the National Cancer Institute</i> , 1994, 86, 1694-1701.	6.3	23
86	Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles. <i>Small</i> , 2018, 14, e1802886.	10.0	23
87	Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. <i>International Journal of Cancer</i> , 2019, 144, 3146-3159.	5.1	23
88	Retinoic Acid Rapidly Decreases Phosphatidylinositol Turnover During Neuroblastoma Cell Differentiation. <i>Journal of Neurochemistry</i> , 1990, 54, 540-546.	3.9	22
89	Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. , 1996, 67, 95-100.		22
90	An interferon-sensitive response element is involved in constitutive caspase-8 gene expression in neuroblastoma cells. <i>International Journal of Cancer</i> , 2007, 120, 39-47.	5.1	21

#	ARTICLE	IF	CITATIONS
91	Nanocarrier-Mediated Targeting of Tumor and Tumor Vascular Cells Improves Uptake and Penetration of Drugs into Neuroblastoma. <i>Frontiers in Oncology</i> , 2013, 3, 190.	2.8	21
92	Fenretinide as an anti-angiogenic agent in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 181-184.	7.2	20
93	Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line. <i>Proteomics</i> , 2006, 6, 4420-4431.	2.2	20
94	The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients. <i>Cancer Research</i> , 2015, 75, 4265-4271.	0.9	20
95	Biological and clinical role of p73 in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 111-117.	7.2	19
96	Drug Delivery Systems: Application of Liposomal Anti-Tumor Agents to Neuroectodermal Cancer Treatment. <i>Tumori</i> , 2008, 94, 246-253.	1.1	19
97	An alternative in vivo system for testing angiogenic potential of human neuroblastoma cells. <i>Cancer Letters</i> , 2009, 277, 199-204.	7.2	19
98	Glycine N-Methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate Formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing. <i>Advanced Functional Materials</i> , 2017, 27, 1701245.	14.9	19
99	Integrin up-regulation as marker of neuroblastoma cell differentiation: correlation with neurite extension. <i>Cell Death and Differentiation</i> , 1997, 4, 713-724.	11.2	18
100	New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against c-Met. <i>Oncotarget</i> , 2015, 6, 28774-28789.	1.8	18
101	Chromogranin A binds to $\alpha 2 \beta 1$ -integrin and promotes wound healing in mice. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 2791-2803.	5.4	17
102	Stimulation of receptor-coupled phospholipase A2 by interferon- $\gamma$ . <i>FEBS Letters</i> , 1992, 310, 17-21.	2.8	16
103	Investigational drugs in phase II clinical trials for the treatment of neuroblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1281-1293.	4.1	16
104	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. <i>Cancers</i> , 2020, 12, 2989.	3.7	16
105	Cotargeting of miR-126 and miR-221 inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling. <i>Molecular Oncology</i> , 2021, 15, 2969-2988.	4.6	16
106	A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. <i>Oncogene</i> , 2021, 40, 6143-6152.	5.9	16
107	A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma. <i>Cancers</i> , 2021, 13, 5528.	3.7	16
108	Morphologic and phenotypic changes of human neuroblastoma cells in culture induced by cytosine arabinoside. <i>Experimental Cell Research</i> , 1989, 181, 226-237.	2.6	15

#	ARTICLE	IF	CITATIONS
109	A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo. <i>Journal of Hepatology</i> , 2016, 65, 75-83.	3.7	15
110	The Olive Leaves Extract Has Anti-Tumor Effects against Neuroblastoma through Inhibition of Cell Proliferation and Induction of Apoptosis. <i>Nutrients</i> , 2021, 13, 2178.	4.1	15
111	Proteomic analysis of an orthotopic neuroblastoma xenograft animal model*1. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 808, 279-286.	2.3	14
112	Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model. <i>Current Drug Targets</i> , 2009, 10, 1021-1027.	2.1	14
113	Fibrin Gels Entrapment of a Poly-Cyclodextrin Nanocarrier as a Doxorubicin Delivery System in an Orthotopic Model of Neuroblastoma: Evaluation of In Vitro Activity and In Vivo Toxicity. <i>Pharmaceutical Research</i> , 2019, 36, 115.	3.5	14
114	Apoptosis of Human Neuroblastoma Cells Induced by Liposome-Encapsulated Fenretinide. <i>Journal of Liposome Research</i> , 1998, 8, 401-423.	3.3	13
115	Targeted Delivery of Oncogene-Selective Antisense Oligonucleotides in Neuroectodermal Tumors: Therapeutic Implications. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 90-103.	3.8	13
116	Chapter 12 Liposome-Mediated Therapy of Neuroblastoma. <i>Methods in Enzymology</i> , 2009, 465, 225-249.	1.0	13
117	Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides. <i>Journal of Controlled Release</i> , 2009, 138, 122-127.	9.9	13
118	Different regulation of mid-size neurofilament and N-myc mRNA expression during neuroblastoma cell differentiation induced by retinoic acid. <i>Cellular and Molecular Neurobiology</i> , 1990, 10, 459-470.	3.3	12
119	γ-interferon, retinoic acid, and cytosine arabinoside induce neuroblastoma differentiation by different mechanisms. <i>Cellular and Molecular Neurobiology</i> , 1991, 11, 397-413.	3.3	12
120	IFN-γ and retinoic acid synergize in inhibiting the growth of human neuroblastoma cells in nude mice. <i>Cancer Letters</i> , 1992, 61, 215-220.	7.2	12
121	Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 195.	8.6	12
122	Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. <i>Journal of Immunology Research</i> , 2018, 2018, 1-12.	2.2	11
123	Induction of 2,5 OAS gene expression and activity is not sufficient for IFN-γ-induced neuroblastoma cell differentiation. <i>International Journal of Cancer</i> , 1995, 62, 223-229.	5.1	10
124	Induction of differentiation and apoptosis by interferon-γ in human neuroblastoma cells in vitro as a dual and alternative early biological response. <i>Cell Death and Differentiation</i> , 1997, 4, 150-158.	11.2	10
125	MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway. <i>Pharmaceuticals</i> , 2022, 15, 297.	3.8	10
126	Retinoic acid inhibits phosphatidylinositol turnover only in RA-sensitive while not in RA-resistant human neuroblastoma cells. <i>Biochemical and Biophysical Research Communications</i> , 1989, 161, 284-289.	2.1	9



#	ARTICLE	IF	CITATIONS
127	Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma. <i>Oncolmunology</i> , 2018, 7, e1468953.	4.6	9
128	Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement. <i>Cancer Research</i> , 2019, 79, 1925-1937.	0.9	9
129	Retinoids Delivery Systems in Cancer: Liposomal Fenretinide for Neuroectodermal-Derived Tumors. <i>Pharmaceuticals</i> , 2021, 14, 854.	3.8	8
130	Immune evaluation of 50 children with neuroblastoma at onset. <i>Medical and Pediatric Oncology</i> , 1982, 10, 321-330.	1.0	7
131	Phosphatidylinositol turnover is not a general regulator of neuroblastoma cell differentiation: comparison between two differentiating agents, retinoic acid and I <sup>3</sup> -interferon. <i>FEBS Letters</i> , 1989, 243, 285-288.	2.8	7
132	Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma. <i>Molecules</i> , 2015, 20, 15893-15909.	3.8	7
133	Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules. <i>Journal of Neuro-Oncology</i> , 1997, 31, 171-180.	2.9	6
134	N-(4-hydroxyphenyl)retinamide inhibits cystogenesis by polycystic epithelial cell lines in vitro. <i>Life Sciences</i> , 1999, 64, PL259-PL265.	4.3	6
135	The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma. <i>Biomedicines</i> , 2022, 10, 659.	3.2	6
136	Anti Gd2-Immunoliposome-Mediated Targeting of [125I] Metaiodobenzylguanidine to Neuroblastoma and Melanoma Cells in Vitro. <i>Journal of Liposome Research</i> , 1999, 9, 367-385.	3.3	5
137	Fibrin gels entrapment of a doxorubicin-containing targeted polyclodextrin: Evaluation of in vivo antitumor activity in orthotopic models of human neuroblastoma. <i>Toxicology and Applied Pharmacology</i> , 2019, 385, 114811.	2.8	5
138	Bone Marrow Environment in Metastatic Neuroblastoma. <i>Cancers</i> , 2021, 13, 2467.	3.7	5
139	Purification to homogeneity and biochemical characterization of two suppressor factors from human malignant T-cells. <i>Biochemical and Biophysical Research Communications</i> , 1988, 150, 702-710.	2.1	4
140	Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma. <i>Pharmacological Research</i> , 2021, 163, 105294.	7.1	4
141	Molecular galactose-galectin association in neuroblastoma cells: An unconventional tool for qualitative/quantitative screening. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600116.	1.6	3
142	Abstract 5144: Oligonucleotide-based inhibition of the pro-angiogenic activity of Hepatoma-derived growth factor related protein 3 in neuroblastoma. , 2011, , .		3
143	Interferon-γ-induced differentiation of human neuroblastoma cells increases cellular uptake and half-life of metaiodobenzylguanidine. <i>Cytotechnology</i> , 1993, 11, S140-S143.	1.6	2
144	Cloning and sequencing of isoform-specific regions of human Ca <sup>2+</sup> -independent protein kinase C (PKC)-encoding genes. <i>Gene</i> , 1994, 141, 307-308.	2.2	2

#	ARTICLE	IF	CITATIONS
145	Liposomal Chemotherapy. , 2011, , 2059-2063.		2
146	Angiogenesis in Malignant and Non-Malignant Pediatric Tumors. , 2008, , 475-486.		1
147	Abstract 5112: Galactose probes hit neuroblastoma cells through a specific galactose-galectin association. Cancer Research, 2016, 76, 5112-5112.	0.9	1
148	Abstract 1453: MicroRNA replacement and RNAi-mediated silencing of ALK as combined targeted therapies for neuroblastoma. Cancer Research, 2014, 74, 1453-1453.	0.9	1
149	Abstract LB-300: In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma. , 2017, , .		1
150	Differential changes in lipid metabolism of myeloid and lymphoid cell lines induced by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). FEBS Letters, 1990, 276, 25-28.	2.8	0
151	Morphological and biochemical modifications during neuroblastoma cell differentiation. Cytotechnology, 1991, 5, 178-179.	1.6	0
152	Abstract A130: Effects of a novel liposomal formulation of fenretinide on human neuroblastoma cell growth, apoptosis and angiogenesis. , 2009, , .		0
153	Abstract C215: EZNâ€2208, a novel pegylated SNâ€38 drug conjugate, markedly inhibits tumor growth and metastatic spreading in preclinical models of human neuroblastoma. , 2009, , .		0
154	Abstract B202: A new curcumin analogue compound endowed with strong antitumor activity against neuroectodermâ€derived cancers. , 2009, , .		0
155	Abstract 3625: Novel phage-display derived peptides for tumor- and vasculature-targeted therapies in neuroblastoma. , 2011, , .		0
156	Abstract 5620: Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.. , 2013, , .		0
157	Abstract 1778: Characterization and anti-tumor functionality of a neuroblastoma-specific peptide, either free or conjugated to nanocarriers. , 2014, , .		0
158	Abstract 2622: New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK. , 2014, , .		0
159	Abstract 3844: A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects. , 2016, , .		0
160	Liposomal Chemotherapy. , 2017, , 2520-2524.		0
161	Abstract 5130: Tumor-penetrating peptide-coated nanoparticles as a novel strategy for the targeted therapy of neuroblastoma. , 2017, , .		0
162	Abstract 3879: Enhancement of tumor penetration by drug-loaded nanoparticles: An innovative targeted strategy for neuroblastoma. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
163	Abstract 2160: Microfragmented human fat tissue is a natural scaffold for drug delivery: potential application in cancer chemotherapy. , 2019, , .		0
164	Abstract A101: Nucleolin: A novel cell surface protein for neuroblastoma targeted therapy. , 2019, , .		0